Corporate
Ultragenyx Crashes 44% After Setrusumab Fails Two Phase 3 Trials
Dec 29, 2025
You're signed outSign in or to get full access.
UP
Ultragenyx Pharmaceutical (RARE)·Earnings Reports
Q3 2025
View earnings summary and analysis
Q1 2025
View earnings summary and analysis
Q4 2024
View earnings summary and analysis
Q3 2024
View earnings summary and analysis
Research analysts covering Ultragenyx Pharmaceutical.